Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
The Manila Times1d
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...
Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...
Bogalusa Mayor Tyrin Truong hires high-profile attorney after facing drug, solicitation of prostitution charges
High-profile attorney Billy Gibbens confirmed to WDSU that he is now representing Bogalusa Mayor Tyrin Truongin in the case.
CURE2d
First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
Targeted Oncology5d
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer
The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.
The Manila Times14h
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
January 2025 - Cingulate completed its final FDA-required study, a food effect study utilizing a single 50-mg dose of ...
CURE22h
FDA Approves Cabometyx for Some Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
The American Journal of Managed Care19h
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 ...
Elevation Oncology stock tumbles on halted drug development
Shares of Elevation Oncology , Inc. (NASDAQ: ELEV) fell by 20% following the announcement that the company will discontinue the development of its drug candidate EO-3021. The decision came after ...